arrow
P

Patrice Verpillat

european medicines agency
H指数:31
被引数:4,241

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

European Medicines Agency multi-stakeholder workshop on innovation in cardiovascular medicines and medical devices in the EU

欧洲药品管理局关于欧盟心血管药物和医疗器械创新的多利益相关方研讨会

2026-07-220
OA
Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data

评估晚期癌症总生存获益:外部对照队列研究结合真实世界数据的作用

2026-02-110
OAAI
Optimizing Patient Registries for Regulatory Decision Making - Key Learnings From an HMA/EMA Multistakeholder Workshop

优化患者登记系统以支持监管决策制定——来自HMA/EMA多利益相关方研讨会的关键经验

2025-06-020
OAAI
Clinical Evidence 2030

临床证据2030

2025-02-140
OAAI
Real-World Evidence to Support EU Regulatory Decision Making-Results From a Pilot of Regulatory Use Cases
2024-07-047
OAAI
Comparative effectiveness of gonadotropins used for ovarian stimulation during assisted reproductive technologies (ART) in France: A real-world observational study from the French nationwide claims database (SNDS)
2023-06-0115
OAAI
Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital
2022-02-012
OAAI
Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany

重组人促卵泡激素 (r-hfsh-alfa) 与高纯度尿人绝经期促性腺激素 (hMG HP) 在辅助生殖技术 (ART) 治疗中的比较有效性: 德国的一项非干预性研究

2021-06-1610
OAAI